227 related articles for article (PubMed ID: 33132070)
1. The American Brachytherapy Society prostate brachytherapy LDR/HDR simulation workshops: Hands-on, step-by-step training in the process of quality assurance.
Frank SJ; Mourtada F; Crook J; Orio PF; Stock RG; Petereit DG; Rossi PJ; Cox BW; Tang C; Kudchadker RJ; Bruno T; Ma J; Sanders J; Keyes M
Brachytherapy; 2020; 19(6):787-793. PubMed ID: 33132070
[TBL] [Abstract][Full Text] [Related]
2. Development, implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents.
Mesko S; Chapman BV; Tang C; Kudchadker RJ; Bruno TL; Sanders J; Das P; Pinnix CC; Thaker NG; Frank SJ
Brachytherapy; 2020; 19(6):738-745. PubMed ID: 32952054
[TBL] [Abstract][Full Text] [Related]
3. The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer.
Bittner NH; Orio PF; Merrick GS; Prestidge BR; Hartford AC; Rosenthal SA
Brachytherapy; 2017; 16(1):59-67. PubMed ID: 28109632
[TBL] [Abstract][Full Text] [Related]
4. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
5. Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer.
Ilg AM; Laviana AA; Kamrava M; Veruttipong D; Steinberg M; Park SJ; Burke MA; Niedzwiecki D; Kupelian PA; Saigal C
Brachytherapy; 2016; 15(6):760-767. PubMed ID: 27720202
[TBL] [Abstract][Full Text] [Related]
6. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix.
Nag S; Erickson B; Thomadsen B; Orton C; Demanes JD; Petereit D
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):201-11. PubMed ID: 10924990
[TBL] [Abstract][Full Text] [Related]
7. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
8. Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program.
Keyes M; Morris WJ; Spadinger I; Araujo C; Cheung A; Chng N; Crook J; Halperin R; Lapointe V; Miller S; Pai H; Pickles T
Brachytherapy; 2013; 12(4):343-55. PubMed ID: 22727470
[TBL] [Abstract][Full Text] [Related]
9. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
10. American Brachytherapy Society-Groupe Européen de Curiethérapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy.
Crook JM; Haie-Meder C; Demanes DJ; Mazeron JJ; Martinez AA; Rivard MJ
Brachytherapy; 2013; 12(3):191-8. PubMed ID: 23453681
[TBL] [Abstract][Full Text] [Related]
11. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
12. Semiconductor real-time quality assurance dosimetry in brachytherapy.
Carrara M; Cutajar D; Alnaghy S; Espinoza A; Romanyukha A; Presilla S; Tenconi C; Cerrotta A; Fallai C; Safavi-Naeini M; Petasecca M; Kejda A; Lerch M; Corde S; Jackson M; Howie A; Bucci J; Rosenfeld AB
Brachytherapy; 2018; 17(1):133-145. PubMed ID: 28964727
[TBL] [Abstract][Full Text] [Related]
13. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy.
Erickson BA; Demanes DJ; Ibbott GS; Hayes JK; Hsu IC; Morris DE; Rabinovitch RA; Tward JD; Rosenthal SA
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):641-9. PubMed ID: 21106308
[TBL] [Abstract][Full Text] [Related]
14. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
Rosenthal SA; Bittner NH; Beyer DC; Demanes DJ; Goldsmith BJ; Horwitz EM; Ibbott GS; Lee WR; Nag S; Suh WW; Potters L; ;
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):335-41. PubMed ID: 21106306
[TBL] [Abstract][Full Text] [Related]
15. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
[TBL] [Abstract][Full Text] [Related]
16. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
[TBL] [Abstract][Full Text] [Related]
17. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.
Yang R; Zhao N; Liao A; Wang H; Qu A
Med Dosim; 2016; 41(3):236-41. PubMed ID: 27400663
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
20. Quality assurance of HDR prostate plans: program implementation at a community hospital.
Rush JB; Thomas MD
Med Dosim; 2005; 30(4):243-8. PubMed ID: 16275567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
